Thomas Shrader

Jason Zemansky

Pete Stavropoulos

Ting Liu

Ananda Ghosh

Cameron Bozdog

Jeff Meacham

Mark Hitrik

Paul Matisse

Paul Matteis

Sarah Madras

Tom Schrader

Trung Huynh

- **Acumen Pharmaceuticals** is developing **sabirnetug**, an **Aβ oligomer-directed antibody**, as a distinct and potentially superior treatment for Alzheimer's disease compared to current options.  **[1576885_tx_380158_0]** 
- The company's confidence in sabirnetug is supported by **Phase 1 INTERCEPT-AD study data (2022-2023)**, which demonstrated target engagement, a competitive safety profile, and positive biomarker effects, with further evidence sought in the ongoing **ALTITUDE-AD study**.  **[1576885_tx_380158_1]** 
- Acumen utilized a **pTau217 plasma screening assay** in the ALTITUDE-AD study, which significantly improved enrollment speed and efficiency, noting its **cost-effectiveness** compared to PET scans.  **[1576885_tx_380158_1]** **[1576885_tx_380158_3]** 
- Future development plans include a **subcutaneous formulation** of sabirnetug, with a Phase 1 study completed, and a collaboration with **JCR Pharmaceuticals** for an **enhanced brain delivery (EBD)** approach, targeting clinical entry for EBD in **2027**.  **[1576885_tx_380158_6]** **[1576885_tx_380158_7]**

Acumen Pharmaceuticals Provides Update on Alzheimer's Drug Sabirnetug Development

Acumen Pharmaceuticals (ABOS)